Previous close | 24.07 |
Open | 24.09 |
Bid | 24.21 x 300 |
Ask | 24.30 x 200 |
Day's range | 24.06 - 24.63 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 2,002,566 |
Market cap | 4.104B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 7.93 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.